AGP Picks
View all

Sci-Tech North Carolina: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Sci-Tech North Carolina.

Press releases published on May 28, 2026

Fixico et Caliber unissent leurs forces pour transformer la réparation de flottes aux États-Unis
Fixico en Caliber bundelen krachten om de Amerikaanse schadeherstelmarkt te transformeren
Virtune informs about a technical update regarding the review date for the Virtune Stablecoin Index (STABLEI) in the index methodology provided by the index provider MarketVector
Virtune informerar om en teknisk uppdatering avseende översynsdatumet för Virtune Stablecoin Index (STABLEI) i indexmetodologin från indexleverantören MarketVector
Agora, der Denodo Cloud Service, ist ab sofort im Microsoft Marketplace verfügbar und unterstützt Anwendungsfälle für agentenbasierte KI
Agora, le service cloud de Denodo, désormais disponible sur Microsoft Marketplace pour accélérer les cas d’usage d’IA agentique
Agora, שירות הענן של Denodo, זמין כעת ב-Microsoft Marketplace כדי להעצים תרחישי שימוש בבינה מלאכותית סוכנית
デノードのクラウドサービスであるアゴラ、マイクロソフト・マーケットプレイスで提供を開始し、エージェント型AIのユースケースを強化
Denodo의 클라우드 서비스 ‘Agora’, Microsoft Marketplace에 출시되며 에이전틱 AI 활용 지원
Agora, Denodo Cloud Service, kini tersedia di Microsoft Marketplace untuk Memacu Kes Penggunaan Agentic AI
Denodo 云服务 Agora 现已上线 Microsoft Marketplace,旨在赋能智能体 AI 应用场景
Denodo 雲端服務 Agora 現已登陸 Microsoft Marketplace,推動代理型 AI 應用場景
Theolytics’ Ongoing US Phase 1 OCTOPOD-IP Trial of THEO-260 in Ovarian Cancer to be Presented as a Trial in Progress at ASCO 2026
Groundbreaking therapy for advanced heart failure: Outcomes of the BIOVAT-HF clinical trial published in NEJM
Enterome receives U.S. FDA Orphan Drug Designation for EO2463 OncoMimics™ to treat “watch-and-wait” indolent non-Hodgkin lymphoma
Trogenix doses first patient in Phase I/II clinical trial of TGX-007 gene therapy for glioblastoma
Azerion publishes Interim Unaudited Financial Results Q1 2026
New late-breaking data reinforces IQIRVO®’s impact on ALP, fatigue and pruritus in PBC
De nouvelles données "late-breaking" renforcent l’impact d’IQIRVO® sur l’ALP, la fatigue et le prurit dans la CBP.
Basilea erhält weitere USD 13 Mio. von BARDA zur Entwicklung des neuartigen Antibiotikums Ceftibuten-Ledaborbactam

Share this page:

Sign up for:

Sci-Tech North Carolina

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.